Corteva (NYSE:CTVA – Get Free Report) had its target price upped by investment analysts at Jefferies Financial Group from $95.00 to $97.00 in a research report issued on Thursday,MarketScreener reports. Jefferies Financial Group’s target price suggests a potential upside of 19.61% from the stock’s current price.
A number of other equities research analysts have also recently weighed in on CTVA. Weiss Ratings reissued a “hold (c)” rating on shares of Corteva in a research report on Wednesday, April 22nd. Bank of America raised their price objective on Corteva from $80.00 to $82.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. UBS Group lifted their target price on Corteva from $80.00 to $88.00 and gave the stock a “neutral” rating in a research report on Thursday, April 9th. The Goldman Sachs Group lifted their target price on Corteva from $88.00 to $96.00 and gave the stock a “buy” rating in a research report on Tuesday, April 14th. Finally, Wells Fargo & Company lifted their target price on Corteva from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 21st. Thirteen equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, Corteva presently has a consensus rating of “Moderate Buy” and an average target price of $87.05.
View Our Latest Report on CTVA
Corteva Stock Performance
Corteva (NYSE:CTVA – Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $1.50 earnings per share for the quarter, topping the consensus estimate of $1.18 by $0.32. Corteva had a net margin of 6.50% and a return on equity of 9.95%. The business had revenue of $4.91 billion during the quarter, compared to the consensus estimate of $4.64 billion. During the same quarter in the previous year, the firm earned $1.13 EPS. The company’s revenue was up 11.0% compared to the same quarter last year. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. Research analysts predict that Corteva will post 3.63 EPS for the current fiscal year.
Insider Transactions at Corteva
In other Corteva news, insider Brian Titus sold 8,311 shares of the company’s stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $76.55, for a total transaction of $636,207.05. Following the completion of the sale, the insider directly owned 8,090 shares of the company’s stock, valued at $619,289.50. This represents a 50.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.15% of the stock is owned by company insiders.
Institutional Inflows and Outflows
A number of institutional investors have recently modified their holdings of the stock. Activest Wealth Management lifted its holdings in shares of Corteva by 118.3% during the third quarter. Activest Wealth Management now owns 369 shares of the company’s stock worth $25,000 after purchasing an additional 200 shares during the period. JPL Wealth Management LLC acquired a new position in Corteva in the 3rd quarter valued at $25,000. Garton & Associates Financial Advisors LLC purchased a new position in Corteva during the 4th quarter worth $27,000. Bank of Jackson Hole Trust purchased a new position in Corteva during the 4th quarter worth $28,000. Finally, Redmont Wealth Advisors LLC acquired a new stake in shares of Corteva in the 3rd quarter worth $29,000. Institutional investors and hedge funds own 81.54% of the company’s stock.
Key Headlines Impacting Corteva
Here are the key news stories impacting Corteva this week:
- Positive Sentiment: Royal Bank of Canada raised Corteva’s price target to $97 from $95 and kept an outperform rating, signaling confidence in roughly 20% upside from recent levels. RBC Capital adjusts Corteva price target to $97 from $95, maintains outperform rating
- Positive Sentiment: Jefferies also increased its target on Corteva to $97 from $95, reinforcing a bullish view on the stock’s longer-term valuation. Jefferies adjusts price target on Corteva to $97 from $95
- Neutral Sentiment: UBS raised its target to $90 from $88 but kept a neutral rating, suggesting limited near-term conviction despite modest upside potential. UBS Group AG price target raise
- Neutral Sentiment: Citigroup lifted its target to $85 from $83 and maintained a neutral rating, indicating some valuation support but no strong bullish call. Citigroup Inc. price target raise
- Neutral Sentiment: Corteva said CEO Chuck Magro and CFO David Johnson will speak at the BMO Global Farm to Market Conference on May 14, a routine investor-relations event with limited immediate impact. Corteva to Participate in BMO Global Farm to Market Conference
- Neutral Sentiment: BNP Paribas Exane nudged its target higher to $77 from $74 but still implied downside from the stock’s recent trading range, making it a mixed signal. BNP Paribas adjusts price target on Corteva to $77 from $74
Corteva Company Profile
Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid?2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.
Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.
Featured Articles
Receive News & Ratings for Corteva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corteva and related companies with MarketBeat.com's FREE daily email newsletter.
